Skip to main content
Premium Trial:

Request an Annual Quote

Sanger Institute, Horizon Discovery Partner on Translation Genomics

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The Wellcome Trust's Sanger Institute and Horizon Discovery today announced they will be collaborating to translate information about human genetic variation into more effective treatments for cancer.

Under the three year partnership, which began last month, Horizon Discovery will "augment" the Sanger Institute's Genomics of Drug Sensitivity in Cancer project with the Massachusetts General Hospital Cancer Center, which was initiated to profile clinical and pre-clinical cancer drugs for their activity on a large collection of human cancer cell lines by identifying genetic markers of drug sensitivity.

Horizon will supply to the project its resource of more than 200 genetically defined "X-Man" in vitro human cancer models that contain known cancer-causing mutations. They will be used for sensitivity profiling against a panel of clinical and pre-clinical cancer drugs, the partners said in a statement.

The Genomics of Drug Sensitivity in Cancer project is a five-year project launched in 2008. In June, researchers involved in it said they were releasing treatment response data and corresponding genomic information for hundreds of cancer samples.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.